 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
| 123456789101112» |
- || alendronate / Generic mfg.
Clinical, Retrospective data, Journal: EFFECT OF XIAOYAO PILLS COMBINED WITH ALENDRONATE ON BONE DENSITY IN POSTMENOPAUSAL PATIENTS WITH OSTEOPOROSIS. (Pubmed Central) - Sep 4, 2024
Xiaoyao Pills combined with alendronate can improve bone density in postmenopausal patients with osteoporosis.
- | Prolia (denosumab) / Amgen, Evenity (romosozumab-aqqg) / Astellas, Amgen, UCB
Journal: Change in spinal bone mineral density as estimated by Hounsfield units following osteoporosis treatment with romosozumab, teriparatide, denosumab, and alendronate: an analysis of 318 patients. (Pubmed Central) - Sep 2, 2024
Patients treated with romosozumab for a mean of 10.5 months and teriparatide for a mean of 23 months experienced improved spinal bone mineral density as estimated by CT-based opportunistic HU. Given the shorter duration of effective treatment, romosozumab may be the preferred medication for optimization of osteoporotic patients in preparation for elective spine fusion surgery.
- | alendronate / Generic mfg.
Journal: Injectable PEG Hydrogels with Tissue-Like Viscoelasticity Formed through Reversible Alendronate-Calcium Phosphate Crosslinking for Cell-Material Interactions. (Pubmed Central) - Sep 2, 2024
This new crosslinking mechanism provides shear-thinning properties resulting in differential cellular responses between cancer cells and stem cells. The novel hydrogel system is an improved design to the other ionic crosslink platforms and opens new avenues for the development of pathologically relevant cancer models, as well as minimally-invasive approaches for cell delivery for potential regenerative therapies.
- | zoledronic acid / Generic mfg., alendronate / Generic mfg.
Journal: Paget's bone disease in a nonendemic region: Exploring novel therapeutic strategies. (Pubmed Central) - Sep 1, 2024
We recommended Fosamax (70?mg alendronate tablets) at two tablets twice weekly for 3?months to manage PDB due to patient preference and side effects with intravenous zoledronic acid. Subsequent assessments of alkaline phosphatase levels during follow-up examinations post-treatment revealed a reduction in their values.
- | alendronate / Generic mfg.
Preclinical, Journal: Long-term passage impacts human dental pulp stem cell activities and cell response to drug addition in vitro. (Pubmed Central) - Aug 28, 2024
Alendronate (ALN) drug treatment was used as an external factor...An increase in passage number played critical role in cell morphology and activities as well as responses to the addition of an external factor. The effects of cell passage should be considered when used in basic science research and clinical applications.
- || Clinical, Retrospective data, Journal: Can Bisphosphonate Therapy Reduce Overall Mortality in Patients With Osteoporosis? A Meta-analysis of Randomized Controlled Trials. (Pubmed Central) - Aug 22, 2024
The primary consideration for prescribing bisphosphonates to individuals with osteoporosis should continue to be centered on reducing fracture risk, aligning with clinical guidelines. Long-term studies are needed to investigate potential effects on mortality during extended treatment periods.
- || Xofigo (radium Ra-223 dichloride) / Bayer
Review, Journal: Role of osteoclast inhibitors in prostate cancer bone metastasis; a narrative review. (Pubmed Central) - Aug 22, 2024
Long-term studies are needed to investigate potential effects on mortality during extended treatment periods. Osteoclast inhibitors are effective in reducing skeletal related events in advanced bone metastasis and improve the quality of life of patients.
- | alendronate / Generic mfg.
Journal: Declining Trend in Anti-osteoporotic Treatment, Despite a Rise in DEXA Screening Following "Sentinel" Distal Radius Fractures. (Pubmed Central) - Aug 21, 2024
Factors associated with increased odds of receiving anti-osteoporotic medication were age 70 to 79 years (odds ratio [OR], 1.45; P = .014), age 80 to 89 years (OR, 1.66; P = .001), Asian (OR, 2.95; P = .002) or Hispanic (OR, 1.77; P = .006) ethnicity, belonging to South (OR, 1.19; P = .029) or West (OR, 1.37; P = .010), and having an Elixhauser Comorbidity Index score of 3 (OR, 2.14; P = .024) or > 3 (OR, 2.05; P = .022). Despite a rising utilization of DEXA screening following "sentinel" distal radius fractures, the proportion of individuals who receive anti-osteoporotic treatment is decreasing over time.
- | alendronate / Generic mfg.
Journal: Intelligent Supramolecular Modification for Implants: Endogenous Regulation of Bone Defect Repair in Osteoporosis. (Pubmed Central) - Aug 21, 2024
Furthermore, osteoblasts secrete alkaline phosphatase (ALP), which significantly hydrolyzes phosphate ester bonds in surface macromolecular side groups, resulting in the release of alendronate (ALN)...This intelligent surface modification tailors bone repair to individual conditions, automatically realize multiple endogenous regulation once implanted, and truly realize spontaneous activation of a series of responses conducive to bone repair in vivo. It is evidenced by improved bone regeneration in iron-overloaded osteoporotic rabbits and supported by in vitro validations.
- | alendronate / Generic mfg.
Journal: Epimedin A inhibits the PI3K/AKT/NF-?B signalling axis and osteoclast differentiation by negatively regulating TRAF6 expression. (Pubmed Central) - Aug 17, 2024
It is evidenced by improved bone regeneration in iron-overloaded osteoporotic rabbits and supported by in vitro validations. The findings indicated that EA can negatively regulate osteoclastogenesis by inhibiting the TRAF6/PI3K/AKT/NF-?B axis and that ameliorating ovariectomy-induced osteoporosis in rats with EA may be a promising potential therapeutic strategy for the treatment of osteoporosis.
- | risedronate / Generic mfg., alendronate / Generic mfg.
Journal: Effects of daily teriparatide, weekly high-dose teriparatide, or bisphosphonate on cortical and trabecular bone of vertebra and proximal femur in postmenopausal women with fragility fracture: Sub-analysis by quantitative computed tomography from the TERABIT study. (Pubmed Central) - Aug 14, 2024
W-PTH had a moderate effect on trabecular bone of vertebra, while it increased both cortical BMD and BV of proximal femur. Although BP had a limited effect on trabecular bone of vertebra compared to teriparatide, it increased both cortical BMD and BV of proximal femur.
- | alendronate / Generic mfg.
Journal: Predictors of discontinuation of osteoporosis treatment: sub-analysis of the Japanese osteoporosis intervention trial-05 (JOINT-05). (Pubmed Central) - Aug 14, 2024
Although BP had a limited effect on trabecular bone of vertebra compared to teriparatide, it increased both cortical BMD and BV of proximal femur. When starting TPTD and ALN treatment, careful attention to patients with lower serum calcium levels and poor cognitive function, respectively, may be needed for better treatment continuity.
- | alendronate / Generic mfg.
Preclinical, Journal: Improvement of osteoblast adhesion, viability, and mineralization by restoring the cell cytoskeleton after bisphosphonate discontinuation in vitro. (Pubmed Central) - Aug 14, 2024
Discontinuation of alendronate helps to reverse the negative effects of the drug on cell viability, cell adhesion, and mineralization by restoring the cell cytoskeleton. Our data suggest the benefits of drug holiday and/or intermittent strategies for alendronate administration at the cellular level.
- | alendronate / Generic mfg.
Journal: Alendronate Functionalized Bone-Targeting Pomolic Acid Liposomes Restore Bone Homeostasis for Osteoporosis Treatment. (Pubmed Central) - Aug 13, 2024
In this study, a novel therapeutic agent was designed and constructed to treat osteoporosis, consisting of a liposome material as the drug pocket, PA as the anti-osteoporosis drug, and ALN as the bone-targeting molecule. And our study is the first to employ a bone-targeted delivery system to deliver PA for OVX-induced bone loss, providing an innovative solution for treating osteoporosis.
- | alendronate / Generic mfg.
Journal: Differences in tissue-level properties as assessed by nano-scratching in patients with and without atypical femur fractures on long-term bisphosphonate therapy: a proof-of-concept pilot study. (Pubmed Central) - Aug 13, 2024
The results of this study are consistent with other studies in the literature and demonstrate the efficacy of using Nano-Scratch technique to evaluate bone tissue that exhibits SSBT and AFF. Further studies using nano-scratch may help quantify and elucidate underlying mechanisms for the pathogenesis of AFF.
- | alendronate / Generic mfg.
Journal: Poloxamer 407 modified collagen/?-tricalcium phosphate scaffold for localized delivery of alendronate. (Pubmed Central) - Aug 4, 2024
Finally, biocompatibility testing demonstrated that the drug delivery system exhibited favorable cytocompatibility and hemocompatibility. Collectively, these findings suggest that the drug delivery system holds promise for implantation and bone healing applications.
- | Prolia (denosumab) / Amgen
Journal: Aromatase inhibitor-induced bone loss osteosarcopenia in older patients with breast cancer: effects of the RANK/RANKL system's inhibitor denosumab vs. bisphosphonates. (Pubmed Central) - Aug 3, 2024
Collectively, these findings suggest that the drug delivery system holds promise for implantation and bone healing applications. This group was matched with 30 patients with non-metastatic breast cancer, who were treated with biphosphonates (BF) therapy (oral alendronate 70
- | ethacrynic acid / Generic mfg., alendronate / Generic mfg., oxcarbazepine / Generic mfg.
FDA event, Preclinical, Journal: In Vivo Chemical Screening in Zebrafish Embryos Identified FDA-Approved Drugs That Induce Differentiation of Acute Myeloid Leukemia Cells. (Pubmed Central) - Jul 31, 2024
Thus, the combination of ethacrynic acid and ATRA may have broader clinical applications. In conclusion, through zebrafish-aided screening, our study identified four drugs that can be repurposed to induce AML differentiation, thus providing new agents for AML therapy.
- | alendronate / Generic mfg.
Journal: Autocatalytic bifunctional supramolecular hydrogels for osteoporotic bone repair. (Pubmed Central) - Jul 29, 2024
Herein, multifunctional self-assembled supramolecular fiber hydrogels (Ce-Aln gel) consisting of alendronate (Aln) and cerium (Ce) ions were constructed for osteoporotic bone defect repair...In vivo experiments showed that the clinical drug-based Ce-Aln gel effectively promoted the tissue repair of osteoporotic bone defects by improving inflammation and inhibiting osteoclast formation at the defect. Notably, in vivo systemic osteoporosis was significantly ameliorated, highlighting the strong potential of clinical translation for precise therapy of bone defects.
- || alendronate / Generic mfg.
Clinical, Journal: Comparing the Effect of Bone-loading Exercises and Pulsed Electromagnetic Fields on Bone Turnover Markers in Women with Osteoporosis: A Randomized Clinical Trial Study Protocol. (Pubmed Central) - Jul 29, 2024
Group A) will receive bone-loading exercises, B) will follow the PEMF(s) and C) will be exposed to the combination of A and B. These three groups will require intervention for 24 sessions (2 sessions/week) next to their routine medical treatment (Alendronate+ Calcium+ Vitamin D)...This trial will provide new practical knowledge on the bone-loading exercises and PEMFS(s)'s effect on PMOP women. This knowledge is of the essence for physiotherapists, clinicians, other healthcare professionals, and policymakers in the healthcare system.
- | alendronate / Generic mfg.
Journal: Alendronate-functionalized porous nano-crystalsomes mitigate osteolysis and consequent inhibition of tumor growth in a tibia-induced metastasis model. (Pubmed Central) - Jul 28, 2024
Further, In vivo intravenous pharmacokinetics showed the improved therapeutic profile of the ALN?+?OA@NCs in comparison to the free drug, prolonging the levels of the drug in the systemic compartment by reducing the clearance culminating the higher accumulation at the tumor site. Our finding proposed that ALN?+?OA@NCs can effectively target and treat breast cancer metastasis to bone and its associated complications.
- || Prolia (denosumab) / Amgen
Retrospective data, Review, Journal: Denosumab vs. bisphosphonates in primary osteoporosis: a meta-analysis of comparative safety in randomized controlled trials. (Pubmed Central) - Jul 28, 2024
However, all trials had a risk of bias. Further investigations are required to confirm our results.
- || Prolia (denosumab) / Amgen, Evenity (romosozumab-aqqg) / Astellas, Amgen, UCB
Clinical, Retrospective data, Review, Journal: Efficacy and Safety of Anti-Osteoporotic Agents Across CKD Stages: A Meta-Analysis of Randomized Clinical Trials. (Pubmed Central) - Jul 26, 2024
However, this benefit is not apparent in stages 4 and 5, necessitating further research. Despite the absence of reported side effects in CKD patients, clinicians should carefully assess the suitability of these medications, considering individual risks and benefits.
- | Prolia (denosumab) / Amgen
Journal: Type 2 diabetes incidence in patients initiating denosumab or alendronate treatment: a primary care cohort study. (Pubmed Central) - Jul 24, 2024
Despite the absence of reported side effects in CKD patients, clinicians should carefully assess the suitability of these medications, considering individual risks and benefits. In this comparative study of older patients seen in routine practices, denosumab was associated with a lower risk of developing T2DM than alendronate.
- | zoledronic acid / Generic mfg., alendronate / Generic mfg.
New P4 trial: A prospective randomized controlled study comparing the efficacy and safety of bisphosphonate and desomumab in the treatment of postmenopausal woman with type 2 diabetes mellitus and osteoporosis: A prospective open-label randomized controlled study comparing the efficacy and safety of bisphosphonates (alendronate or zoledronic acid) versus desomumab in the treatment of postmenopausal woman with type 2 diabetes mellitus and osteoporosis (EUDRACT) - Jul 15, 2024
P4, N=200, Recruiting, Sponsor: Tongji Hospital, Tongji University School of Medicine; Tongji Hospital, Tongji University School of Medicine
- || Evenity (romosozumab-aqqg) / Astellas, Amgen, UCB
Trial completion, Trial completion date: Romosozumab in Women With Chronic SCI (clinicaltrials.gov) - Jul 14, 2024
P2, N=12, Completed, Sponsor: Northwestern University
In this comparative study of older patients seen in routine practices, denosumab was associated with a lower risk of developing T2DM than alendronate. Active, not recruiting --> Completed | Trial completion date: Feb 2025 --> Jun 2024
- | Journal: Comparison table: Some drugs for postmenopausal osteoporosis. (Pubmed Central) - Jul 9, 2024
Active, not recruiting --> Completed | Trial completion date: Feb 2025 --> Jun 2024 No abstract available
- || Review, Journal: Drugs for postmenopausal osteoporosis. (Pubmed Central) - Jul 9, 2024
No abstract available No abstract available
- || Prolia (denosumab) / Amgen
Clinical, Retrospective data, Review, Journal, Metastases: Bone-modifying agents for reducing bone loss in women with early and locally advanced breast cancer: a network meta-analysis. (Pubmed Central) - Jul 9, 2024
Therefore, forming an overall judgement of the best ranked bone-modifying agent is challenging. More head-to-head comparisons, especially comparing denosumab with any bisphosphonate, are needed to address gaps and validate the findings of this review.
- | Remicade (infliximab) / J&J, Tremfya (guselkumab) / J&J
Journal: Long-term clinical course of two rare cases of synovitis-acne-pustulosis-hyperostosis-osteomyelitis syndrome involving only unilateral femur. (Pubmed Central) - Jul 8, 2024
X-rays of the femur showed cortical thickening. SAPHO syndrome can be managed with drug therapies, such as nonsteroidal anti-inflammatory drugs, methotrexate, and conventional synthetic disease-modifying antirheumatic drugs; however, there are occasional treatment-resistant cases.
- | alendronate / Generic mfg.
Journal: Association of bisphosphonate with bone loss and pain-related behavior in an adjuvant-induced osteoporosis model. (Pubmed Central) - Jul 6, 2024
SAPHO syndrome can be managed with drug therapies, such as nonsteroidal anti-inflammatory drugs, methotrexate, and conventional synthetic disease-modifying antirheumatic drugs; however, there are occasional treatment-resistant cases. Alendronate may contribute to pain improvement through the simultaneous effects of bone mass improvement and suppression of osteoporotic pain.
- || raloxifene hydrochloride / Generic mfg., alendronate / Generic mfg.
Review, Journal: Antiosteoporosis therapy after discontinuation of menopausal hormone therapy: a systematic review. (Pubmed Central) - Jul 2, 2024
Antiresorptive therapy with either a bisphosphonate (i.e., alendronate) or raloxifene could be considered a sequential antiosteoporosis therapy after MHT withdrawal since they have been shown in studies to further increase BMD. However, no safe conclusions can be drawn from the existing literature.
- | alendronate / Generic mfg.
Journal: Alendronate/lactoferrin-dual decorated lipid nanocarriers for bone-homing and active targeting of ivermectin and methyl dihydrojasmonate for leukemia. (Pubmed Central) - Jul 1, 2024
However, no safe conclusions can be drawn from the existing literature. Ex-vivo hemocompatibility and in-vivo biocompatibility of Aln/Lf/IVM-NLC (1
- | alendronate / Generic mfg.
Journal: Treatment of Medication-Related Osteonecrosis of the Jaws (MRONJ) with Topical Therapy Using Active Oxygen Gel. (Pubmed Central) - Jul 1, 2024
A 63-year-old female patient that had been taking weekly sodium alendronate (70 mg) for four years by oral via, presented discomfort and implant movement in the #46 region, by that underwent surgical extraction of the implant...The patient remains under clinical follow-up. Therefore, it can be concluded that the application of blue
- | pegylated liposomal doxorubicin / Generic mfg., alendronate / Generic mfg.
Biomarker, Journal, Tumor microenvironment: Tumor microenvironment reprogramming improves nanomedicine-based chemo-immunotherapy in sarcomas. (Pubmed Central) - Jun 28, 2024
Therefore, it can be concluded that the application of blue Collectively, our findings provide evidence that ketotifen-induced TME reprograming can improve the efficacy of nanomedicine-based chemoimmunotherapy in sarcomas.
- | alendronate / Generic mfg.
Retrospective data, Journal, Real-world evidence, Real-world: Analysis of medication treatment for women with osteoporosis: A real-world retrospective study from Chinese tertiary grade A hospital. (Pubmed Central) - Jun 28, 2024
The most commonly prescribed medications for this population were calcitriol, calcium carbonate with vitamin D3, and alendronate sodium with vitamin D3. The use of MHT was relatively limited.
- | alendronate / Generic mfg.
Preclinical, Journal: Onion (Allium cepa L.) Flavonoid Extract Ameliorates Osteoporosis in Rats Facilitating Osteoblast Proliferation and Differentiation in MG-63 Cells and Inhibiting RANKL-Induced Osteoclastogenesis in RAW 264.7 Cells. (Pubmed Central) - Jun 27, 2024
The levels of estradiol (E2), calcium (Ca), and phosphorus (P) in serum were significantly increased in ovariectomized (OVX) rats, with effects equal to alendronate sodium (ALN)...Additionally, RANKL-induced osteoclastogenesis and osteoclast activity were inhibited by OFE treatment through decreased TRAP activity and down-regulation of mRNA expression-related enzymes in RAW 264.7 cells. Overall findings suggest that OFE holds promise as a natural functional component for alleviating osteoporosis.
- | alendronate / Generic mfg.
Journal: Defect-Engineered Metal-Organic Frameworks as Nanocarriers for Pharmacotherapy: Insights into Intracellular Dynamics at The Single Particle Level. (Pubmed Central) - Jun 26, 2024
DFT reveals the stronger binding of ATTO 655 to the Zr6 cluster nodes compared with phosphate and Alendronate Sodium...This strategy mitigates colocalization value inflation from high or low signal expression in endo/lysosomal compartments. The results accurately measure the nanoMOFs' colocalization from early to late endosomes and lysosomes and emphasize the importance of understanding their intracellular dynamics based on single-particle tracking for optimal and safe drug delivery.
- | alendronate / Generic mfg.
Journal: Bisphosphonate effectiveness in patients with cirrhosis: An emulated clinical trial. (Pubmed Central) - Jun 26, 2024
In a nationally representative cohort of elderly patients with cirrhosis, bisphosphonates reduced fractures overall. Efforts to increase uptake and drug continuation are needed.
- | risedronate / Generic mfg., zoledronic acid / Generic mfg., alendronate / Generic mfg.
Journal: Drug holidays with bisphosphonates in osteoporosis treatment: one size does not fit all. (Pubmed Central) - Jun 26, 2024
Efforts to increase uptake and drug continuation are needed. No abstract available
- | alendronate / Generic mfg.
Journal: Alendronate as Bioactive Coating on Titanium Surfaces: An Investigation of CaP-Alendronate Interactions. (Pubmed Central) - Jun 19, 2024
This integrated experimental-theoretical study highlights the spontaneous formation of CaP on the alendronate-coated titanium surface, confirming the bioactivity ability of the alendronate coating. The results provide valuable guidance for the promising forthcoming advancements in the development of biomaterials and surface modification of dental implants.
- | alendronate / Generic mfg.
Journal: Farnesyl Diphosphate Synthase Gene Associated with Loss of Bone Mass Density and Alendronate Treatment Failure in Patients with Primary Osteoporosis. (Pubmed Central) - Jun 19, 2024
The results provide valuable guidance for the promising forthcoming advancements in the development of biomaterials and surface modification of dental implants. Higher expression of the FDPS gene was also observed in OP-NR group (FC = 1.84
- | Foscan (temoporfin) / ABVC BioPharma
Journal: Temoporfin-Conjugated PEGylated Poly(N,N-dimethylacrylamide)-Coated Upconversion Colloid for NIR-Induced Photodynamic Therapy of Pancreatic Cancer. (Pubmed Central) - Jun 18, 2024
The designed particles were well tolerated by the human pancreatic adenocarcinoma cell lines CAPAN-2, PANC-1, and PA-TU-8902. After intratumoral injection of mTHPC-conjugated polymer-coated UCNPs and subsequent exposure to 980 nm NIR light, excellent PDT efficacy was achieved in tumor-bearing mice.
- | alendronate / Generic mfg.
Journal: Injectable and high-strength PLGA/CPC loaded ALN/MgO bone cement for bone regeneration by facilitating osteogenesis and inhibiting osteoclastogenesis in osteoporotic bone defects. (Pubmed Central) - Jun 14, 2024
Currently, we developed the PLGA electrospun nanofiber sheets to carry alendronate (ALN) and magnesium oxide nanoparticle (nMgO) into CPC, therefore, to obtain a high-strength bone cement (C/AM-PL/C)...Moreover, the injection of C/AM-PL/C cement significantly improved bone healing in an OP model with femur condyle defects in vivo. Altogether, the injectable C/AM-PL/C cement could facilitate osteoporotic bone regeneration, demonstrating its capacity as a promising candidate for treatment of osteoporotic bone defects.
- | alendronate / Generic mfg.
Preclinical, Journal, IO biomarker: Synergistic effect of Toll-like receptor 2 ligands and alendronate on proinflammatory cytokine production in mouse macrophage-like RAW-ASC cells is accompanied by upregulation of MyD88 expression. (Pubmed Central) - Jun 13, 2024
Altogether, the injectable C/AM-PL/C cement could facilitate osteoporotic bone regeneration, demonstrating its capacity as a promising candidate for treatment of osteoporotic bone defects. Our findings suggest that ALN augments TLR2 ligand-induced proinflammatory cytokine production via the upregulation of MyD88 expression, and this augmentation is accompanied by the activation of NF-?B and AP-1 in RAW-ASC cells.
- | alendronate / Generic mfg.
Observational data, Journal: Osteoporosis treatment prevents hip fracture similarly in both sexes: the FOCUS observational study. (Pubmed Central) - Jun 11, 2024
At two-year follow-up, 33.9% of the women (750/2211 patients) and 24.0% of the men (175/728 patients) were treated, primarily with alendronate; 51.3% and 66.3%, respectively, were not-treated; and 721 and 269, respectively, had a first hip fracture since the CT scan...Various sensitivity and stratified analyses confirmed these trends, including results at five-year follow-up. Given these results and considering the relevant literature, we conclude that osteoporosis treatment prevents hip fracture similarly in both sexes.
- | alendronate / Generic mfg.
Journal: Fluffy hybrid nanoadjuvants for reversing the imbalance of osteoclastic and osteogenic niches in osteoporosis. (Pubmed Central) - Jun 7, 2024
Despite the development of nationally recognized first-line anti-osteoporosis drugs, including alendronate (AL), their low bioavailability, poor uptake rate, and dose-related side effects present significant challenges in treatment...Therefore, this study constructed a drug nanoadjuvant with peculiar topological structures and high bone targeting capacities, efficient intracellular drug delivery as well as bone bioactivity. This provides a novel perspective on drug delivery for osteoporosis and treatment strategies for other bone diseases.
- | Prolia (denosumab) / Amgen
Journal: Atypical metatarsal fracture in a Chinese postmenopausal woman with osteoporosis on long-term denosumab: a case report. (Pubmed Central) - Jun 6, 2024
This provides a novel perspective on drug delivery for osteoporosis and treatment strategies for other bone diseases. No abstract available
- || Retrospective data, Review, Journal: Dental Implant Failure in Post-Menopausal Women on Oral Bisphosphonates: A Systematic Review and Meta-Analysis. (Pubmed Central) - Jun 5, 2024
Risedronate was used in 6 studies, while ibandronate was used in 4 studies...Overall, the qualitative assessment of this review suggests that oral treatment with BPs in post-menopausal women does not increase the rate of dental implant failure. Thus, further studies with larger sample sizes should compare BP and non-BP groups in regard to dental implants.
- | Journal: Bisphosphonates synergistically enhance the antifungal activity of azoles in dermatophytes and other pathogenic molds. (Pubmed Central) - Jun 5, 2024
We extended the study to molds that cause invasive disease, finding synergy in some problematic species. We suggest bisphosphonates could be repurposed as synergents for tinea treatment, and that this combination could be fast-tracked for use in clinical therapy.